DOCSLIB.ORG

Azanidazole/Diaveridine 831 American Trypanosomiasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Azanidazole/Diaveridine 831 American trypanosomiasis. Available treatment for Ameri- ble in water; practically insoluble in alcohol; very slightly solu- can trypanosomiasis (p.827) is generally unsatisfactory, but ben- ble in chloroform and in ether. znidazole is of value especially in the acute phase. WHO1 recom- Cl USP 31 (Decoquinate). Store in airtight containers. mends that benznidazole should be given for 60 days but some in the USA2 suggest courses of 30 to 90 days. Although treat- Profile Decoquinate is an antiprotozoal used in veterinary practice for ment is usually confined to the acute phase of the disease, thera- 3 the control of coccidiosis in calves, sheep, and chickens. It is also py during the early chronic phase was reported to be beneficial, N used for toxoplasmosis in sheep. and long-term follow-up in patients who had received benznida- zole has shown a reduction in cardiac complications and parasi- O N 4 taemia. HN 1. WHO. Control of Chagas disease: second report of the WHO OClN Dehydroemetine Hydrochloride (BANM, rINNM) expert committee. WHO Tech Rep Ser 905 2002. Available at: http://libdoc.who.int/trs/WHO_TRS_905.pdf (accessed BT-436; Déhydroémétine, Chlorhydrate de; 2,3-Dehydroemet- 17/07/08) Pharmacopoeias. In Eur. (see p.vii) for veterinary use only. ine Hydrochloride; Dehydroemetini Hydrochloridum; DHE; 2. Abramowicz M, ed. Drugs for parasitic infections. 1st ed. New Ph. Eur. 6.2 (Clazuril for Veterinary Use; Clazuril BP(Vet) 2008). Hidrocloruro de dehidroemetina; Ro-1-9334. 2,3-Didehydro- Rochelle NY: The Medical Letter, 2007. A white or light yellow powder. Practically insoluble in water; 6′,7′,10,11-tetramethoxyemetan dihydrochloride; 3-Ethyl- 3. de Andrade ALSS, et al. Randomised trial of efficacy of benzni- slightly soluble in alcohol and in dichloromethane; freely soluble 1,6,7,11b-tetrahydro-9,10-dimethoxy-2-(1,2,3,4-tetrahydro-6,7- dazole in treatment of early Trypanosoma cruzi infection. Lancet in dimethylformamide. Protect from light. dimethoxy-1-isoquinolylmethyl)-4H-benzo[a]quinolizine dihydro- 1996; 348: 1407–13. chloride. 4. Viotti R, et al. Treatment of chronic Chagas’ disease with benz- Profile nidazole: clinical and serologic evolution of patients with long- Clazuril is an antiprotozoal used in veterinary practice for the Дегидроэметина Гидрохлорид term follow-up. Am Heart J 1994; 127: 151–62. control of coccidiosis in pigeons. C29H38N2O4,2HCl = 551.5. Preparations CAS — 4914-30-1 (dehydroemetine); 2228-39-9 (dehydro- emetine hydrochloride). Proprietary Preparations (details are given in Part 3) Clefamide (BAN, rINN) Arg.: Radanil; Braz.: Rochagan; Ecuad.: Ragonil. Chlorphenoxamide; Clefamida; Cléfamide; Clefamidum. 2,2- H3CO Dichloro-N-(2-hydroxyethyl)-N-[4-(4-nitrophenoxy)benzyl]- acetamide. N Buparvaquone (BAN, rINN) Клефамид H3CO H Buparvacuona; Buparvaquonum; BW-720C. trans-2-(4-tert- C H Cl N O = 399.2. 17 16 2 2 5 CH3 Butylcyclohexylmethyl)-3-hydroxy-1,4-naphthoquinone. CAS — 3576-64-5. Бупарвахон ATC — P01AC02. C21H26O3 = 326.4. OCH3 HN CAS — 88426-33-9. Cl ATC Vet — QP51AX22. O O OCH Cl 3 O N (dehydroemetine) O2N OH NOTE. The name DHE has been used to denote a preparation of Profile dihydroergotamine mesilate. CH3 Clefamide is an antiprotozoal that has been used as a luminal Pharmacopoeias. In Int. OH amoebicide in the treatment of Entamoeba histolytica infections. CH H C 3 Profile O 3 Dehydroemetine, a synthetic derivative of emetine (p.833), is a tissue amoebicide with similar actions and uses, although proba- Profile Clopidol (BAN, USAN, rINN) bly of a lower toxicity. Buparvaquone is an antiprotozoal used in veterinary practice for Clopidolum; Clopindol; Meticlorpindol. 3,5-Dichloro-2,6- Dehydroemetine should be avoided in patients with cardiac, the treatment of theileriosis in cattle. dimethylpyridin-4-ol. renal, or neuromuscular disease and patients should be moni- tored for cardiac toxicity during treatment. Клопидол When used in the treatment of amoebiasis (p.822), dehydroeme- C7H7Cl2NO = 192.0. tine hydrochloride is given by intramuscular injection in a dose Carnidazole (BAN, USAN, pINN) CAS — 2971-90-6. of 1 mg/kg daily (maximum daily dose of 60 mg), generally for Carnidazol; Carnidazolum; R-25831; R-28096 (carnidazole hy- up to 4 to 6 days, but for no more than 5 days in children. A dose drochloride). O-Methyl [2-(2-methyl-5-nitroimidazol-1-yl)ethyl]- of 0.5 mg/kg has been suggested for elderly or severely ill pa- H3C N CH3 tients. At least 6 weeks should elapse before treatment is repeat- thiocarbamate. ed. Following treatment with dehydroemetine, all patients Карнидазол should receive a luminal amoebicide to eliminate organisms C H N O S = 244.3. Cl Cl from the colon. Patients with hepatic amoebiasis may be given 8 12 4 3 supplementary treatment with chloroquine. CAS — 42116-76-7. OH ATC Vet — QP51AA09. Liver fluke infections. Dehydroemetine has been given1 in the treatment of the liver fluke infection fascioliasis (see p.137). Profile Clopidol is an antiprotozoal used in veterinary practice for the 1. Farid Z, et al. Treatment of acute toxaemic fascioliasis. Trans R Soc Trop Med Hyg 1988; 82: 299. H3C prevention of coccidiosis in poultry and rabbits either alone or with methyl benzoquate (p.837). N N Diaveridine (BAN, USAN, rINN) HN Decoquinate (BAN, USAN, rINN) BW-49-210; Diaveridina; Diavéridine; Diaveridinum; NSC- + S O N 408735. 5-Veratrylpyrimidine-2,4-diyldiamine. - Décoquinate; Decoquinato; Decoquinatum; HC-1528; M&B- O CH3 O 15497. Ethyl 6-decyloxy-7-ethoxy-4-hydroxyquinoline-3-carbox- Диаверидин ylate. C13H16N4O2 = 260.3. Profile Декохинат CAS — 5355-16-8. ATC Vet — QP51AX18. Carnidazole is a 5-nitroimidazole derivative similar to metroni- C24H35NO5 = 417.5. dazole. It is used in veterinary practice for the control of tricho- CAS — 18507-89-6. moniasis in pigeons. ATC Vet — QP51AX14. H3CO N NH2 H3C O N N Clazuril (BAN, USAN, rINN) H3CO (CH ) Clazurilo; Clazurilum; Klatsuriili; Klazuril; R-62690. (±)-[2-Chloro- 2 9 O CH3 NH H C 2 4-(4,5-dihydro-3,5-dioxo-as-triazin-2(3H)-yl)phenyl]-(p-chloro- 3 O phenyl)acetonitrile. OH O Pharmacopoeias. In Fr. for veterinary use. Клазурил Profile Pharmacopoeias. In US for veterinary use only. Also in C H Cl N O = 373.2. Diaveridine is an antiprotozoal used in veterinary practice for the 17 10 2 4 2 BP(Vet). control of coccidiosis in poultry. CAS — 101831-36-1. BP(Vet) 2008 (Decoquinate). A cream to buff-coloured, ATC Vet — QP51AJ02. odourless or almost odourless, microcrystalline powder. Insolu- The symbol † denotes a preparation no longer actively marketed The symbol ⊗ denotes a substance whose use may be restricted in certain sports (see p.vii) 832 Antiprotozoals Diclazuril (BAN, USAN, rINN) ing broxyquinoline and diiodohydroxyquinoline, have been re- ported elsewhere. Diclazurilo; Diclazurilum; Diklatsuriili; Diklazuril; R-64433. (±)-4- 3 ClCH Chlorophenyl[2,6-dichloro-4-(2,3,4,5-tetrahydro-3,5-dioxo- Diiodohydroxyquinoline has also been associated with gastroin- 1,2,4-triazin-2-yl)phenyl]acetonitrile. testinal effects such as abdominal cramps, nausea, and diarrhoea. N Adverse effects which may be attributable to the iodine content Cl Диклазурил of diiodohydroxyquinoline include pruritus ani, skin eruptions, C H Cl N O = 407.6. and enlargement of the thyroid gland. Fever, chills, headache, O 17 9 3 4 2 HO CAS — 101831-37-2. and vertigo have also occurred. ATC Vet — QP51AJ03. Precautions (diloxanide) Diiodohydroxyquinoline is contra-indicated in patients known to be hypersensitive to iodine or halogenated hydroxyquinolines N and in those with hepatic or renal impairment. It should be used Pharmacopoeias. In Br., Int., and US. with caution in thyroid disease and may interfere with determi- BP 2008 (Diloxanide Furoate). A white or almost white, odour- Cl nations of protein-bound iodine in tests for thyroid function for less or almost odourless, crystalline powder. Very slightly solu- up to 6 months after therapy. Its use is best avoided in patients ble in water; slightly soluble in alcohol and in ether; freely solu- O with neurological disorders. Long-term use should be avoided. ble in chloroform. Protect from light. Children. The Committee on Drugs of the American Academy USP 31 (Diloxanide Furoate). A white or almost white, crystal- line powder. Very slightly soluble in water; slightly soluble in al- Cl Cl NNH of Pediatrics1 considered that there was a potential risk of toxic- ity to infants and children from clioquinol and diiodohydroxy- cohol and in ether; freely soluble in chloroform. Store in airtight N quinoline applied topically. Since alternative effective prepara- containers. Protect from light. O tions are available for dermatitis, the Committee recommended that products containing either of these compounds should not be Adverse Effects Pharmacopoeias. In Eur. (see p.vii) for veterinary use only. used. Flatulence is the most common adverse effect during Ph. Eur. 6.2 (Diclazuril for Veterinary Use; Diclazuril BP(Vet) WHO considers that the use of halogenated hydroxyquinolines treatment with diloxanide furoate. Vomiting, pruritus, 2008). A white or light yellow powder. Practically insoluble in for the treatment of acute diarrhoea or amoebiasis in children water, in alcohol, and in dichloromethane; sparingly soluble in cannot be justified.2 There is no evidence of their efficacy in and urticaria may occasionally occur. dimethylformamide. Protect from light. acute diarrhoea and they have been associated with severe neu- Profile rological effects. On the rare occasions when a luminal amoebi- Pharmacokinetics Diclazuril is an antiprotozoal that has been tried in AIDS patients cide is required, other less toxic and more effective agents are Diloxanide furoate is hydrolysed before absorption for the management of diarrhoea associated with protozoal infec- available. from the gastrointestinal tract. The resulting diloxanide tion. It is used in veterinary practice for the control of coccidiosis 1. Kauffman RE, et al. American Academy of Pediatrics Commit- in lambs and poultry.
Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • A Screening-Based Approach to Circumvent Tumor Microenvironment

    A Screening-Based Approach to Circumvent Tumor Microenvironment

    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
  • The Alkaloid Emetine As a Promising Agent for the Induction and Enhancement of Drug-Induced Apoptosis in Leukemia Cells

    The Alkaloid Emetine As a Promising Agent for the Induction and Enhancement of Drug-Induced Apoptosis in Leukemia Cells

    737-744 26/7/07 08:26 Page 737 ONCOLOGY REPORTS 18: 737-744, 2007 737 The alkaloid emetine as a promising agent for the induction and enhancement of drug-induced apoptosis in leukemia cells MAREN MÖLLER1, KERSTIN HERZER3, TILL WENGER2,4, INGRID HERR2 and MICHAEL WINK1 1Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Im Neuenheimer Feld 364; 2Molecular OncoSurgery, Department of Surgery, University and German Cancer Research Center, Im Neuenheimer Feld 365, 69120 Heidelberg; 31st Department of Internal Medicine, University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany; 4Centre d'Immunologie de Marseille-Luminy, Marseille, France Received January 8, 2007; Accepted February 20, 2007 Abstract. Emetine, a natural alkaloid from Psychotria caused mainly by two isoquinoline alkaloids, emetine and ipecacuanha, has been used in phytomedicine to induce cephaeline, having identical effects regarding the irritation of vomiting, and to treat cough and severe amoebiasis. Certain the respiratory tract (1). Nowadays, ipecac syrup is no longer data suggest the induction of apoptosis by emetine in recommended for the routine use in the management of leukemia cells. Therefore, we examined the suitability of poisoned patients (2) and recently a guideline on the use of emetine for the sensitisation of leukemia cells to apoptosis ipecac syrup was published, stating that ‘the circumstances in induced by cisplatin. In response to emetine, we found a which ipecac-induced emesis is the appropriate or desired strong reduction in viability, an induction of apoptosis and method of gastric decontamination are rare’ (3). Moreover, at caspase activity comparable to the cytotoxic effect of present there is a demand to remove ipecac from the over- cisplatin.
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Pharmaceutical Appendix to the Harmonized Tariff Schedule

    Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2019) Revision 13 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
  • Cutaneous Amebiasis in Pediatrics

    Cutaneous Amebiasis in Pediatrics

    OBSERVATION Cutaneous Amebiasis in Pediatrics Mario L. Magan˜a, MD; Jorge Ferna´ndez-Dı´ez, MD; Mario Magan˜a,MD Background: Cutaneous amebiasis (CA), which is still Conclusions: Cutaneous amebiasis always presents with a health problem in developing countries, is important painful ulcers. The ulcers are laden with amebae, which to diagnose based on its clinical and histopathologic are relatively easy to see microscopically with routine features. stains. Erythrophagocytosis is an unequivocal sign of CA. Amebae reach the skin via 2 mechanisms: direct and in- Observations: Retrospective medical record review of direct. Amebae are able to reach the skin if there is a lac- 26 patients with CA (22 adults and 4 children) treated from eration (port of entry) and if conditions in the patient 1955 to 2005 was performed. In addition to the age and are favorable. Amebae are able to destroy tissues by means sex of the patients, the case presentation, associated ill- of their physical activity, phagocytosis, enzymes, secre- ness or factors, and method of establishing the diagnosis, tagogues, and other molecules. clinical pictures and microscopic slides were also analyzed. Arch Dermatol. 2008;144(10):1369-1372 UTANEOUS AMEBIASIS (CA) ria, are opportunistic organisms that act as can be defined as damage pathogens, usually in the immunocompro- to the skin and underly- mised host, who can develop disease in any ing soft tissues by tropho- organ, such as the skin and central ner- zoites of Entamoeba histo- vous system. This kind of amebiasis has be- lytica, the only pathogenic form for humans. come more common during the last few C 8-18 Cutaneous amebiasis may be the only ex- years.
  • ED227273.Pdf

    ED227273.Pdf

    DOCUMENT RESUft ED 227 273 y CE 035 300 ' TITLE APharmacy Spicialist, Militkry Curriculum Materials for Vocation47 andileChlaical Education. INSTITuTION Air Force Training Command, Sheppa* AFB, Tex.; Ohio State Univ., Columbus. Natfonal Center for Research in Vocational Education. SPONS AGENCY Office of Education (DHEW)x Washington, D.C. PUB DATE 18 Jul 75 NOTE 774p.; Some pages are marginally legible. ,PUB TYPE Guides - Classroom Use Guides (For Teachers) (052), , EDRS ?RICE 14P05/PC31 Plus Postage. ` DESCRIPTORS Behavioral Objectives; Course Descriptions; A Curriculum Guides; Drug Abuse; Drug,Therapy; 4Drug Use; Learning Activities; Lesson Plans; *Pharmaceutical Education; Pharmacists; *Pharmacology; *Pharmacy; Postsecondary Education; Programed Instructional Materials; Textbooks; Workbooks IDENTIFIERS. Military CuFr.iculum Project liBSTRACT These teacher and studdnt,materials for a . postsecondary-level course in pharmacy comprise one of a numberof military-developed curriculum packages selected for adaptation to voCational instruction 'and curriculum dei7elopment in acivilian setting. The purpose stated for the 256-hour course iS totrain students in the basic technical phases of pharmacy and theminimum essential knowledge and skills necessaryior.the compounding and - dispensing of drugs, the economical operation of a pharmacy,and the proper use of drugs, chemicals, andbiological products. The course consists of three blocks of instruction. Block I contains four, lessons: pharmaceutical calculations I and laboratory,inorganic chemistry, and organic chemistry. The five lessons in Block II cover anatomy ,and physiology, introduction topharmacoloe, toxicology, drug abuse, and pharmaceutical and medicinal agents. Block III provides five lessons: phdrmaceutical calculations\I and II, techniques"of pharmaceutical compounding, pharmaceutiCal dosage for s, and compounding laboratbry. Instructormaterials include a cb se chart, lesson plans, and aplan of instruction detailing instructional,bnits, criterion objectives, lesson duration,and support materials needed.
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al

    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units

    European Surveillance of Healthcare-Associated Infections in Intensive Care Units

    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0271923 A1 Reid (43) Pub

    (12) Patent Application Publication (10) Pub. No.: US 2014/0271923 A1 Reid (43) Pub

    US 20140271923A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0271923 A1 Reid (43) Pub. Date: Sep. 18, 2014 (54) COMPOSITIONS & FORMULATIONS FOR (52) U.S. Cl. PREVENTING AND TREATING CHRONIC CPC ............. A6 IK3I/122 (2013.01); A61 K38/063 DISEASES THAT CLUSTER IN PATIENTS (2013.01); A61 K3I/496 (2013.01); A61 K SUCH AS CARDIOVASCULAR DISEASE, 45/06 (2013.01); A61 K31/4164 (2013.01); DLABETES, OBESITY, POLYCYSTIC OVARY A61K 31/12 (2013.01); A61 K3I/375 SYNDROME, HYPERLIPIDEMIA AND (2013.01); A61 K3I/355 (2013.01) HYPERTENSION, ASWELLAS FOR USPC ..... 424/651: 514/690: 514/21.9; 514/254.07; PREVENTING AND TREATING OTHER 514/383: 514/365: 514/256; 514/398: DISEASES AND CONDITIONS 514/236.2: 514/314: 514/154: 514/311; 514/31; 514/77; 514/39; 514/275; 514/253.08 (71) Applicant: Christopher Brian Reid, Los Angeles, CA (US) (57) ABSTRACT Patients inflicted with various clustering chronic diseases (72) Inventor: Christopher Brian Reid, Los Angeles, require treatment with multiple drugs having distinct mecha CA (US) nisms of action. Accordingly, patients with multiple condi tions suffer from cumulative side effects of multiple drugs as (21) Appl. No.: 13/815,664 well as drug-drug interactions. Embodiments, agents, com pounds or drugs of the present invention, such as sesquiter (22) Filed: Mar 14, 2013 penes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disor Publication Classification ders prevented or ameliorated by administration of the for mulations of this invention include but are not limited to (51) Int.
  • Pharmacy Data Management Drug Exception List

    Pharmacy Data Management Drug Exception List

    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
  • Summary Report on Antimicrobials Dispensed in Public Hospitals

    Summary Report on Antimicrobials Dispensed in Public Hospitals

    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .